Alpha Tau Medical (NASDAQ:DRTS) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Alpha Tau Medical (NASDAQ:DRTS) in a research note released on Tuesday,Benzinga reports. They currently have a $12.00 price target on the stock.

Several other equities analysts have also recently issued reports on the stock. Citigroup reduced their price target on shares of Alpha Tau Medical from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday, December 10th. Piper Sandler restated a “neutral” rating and issued a $5.00 price objective on shares of Alpha Tau Medical in a report on Wednesday, March 4th. Zacks Research raised Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $8.00.

Alpha Tau Medical Stock Up 1.9%

Shares of Alpha Tau Medical stock opened at $6.84 on Tuesday. The company has a market cap of $580.17 million, a PE ratio of -12.91 and a beta of 1.02. The business has a 50 day moving average of $6.97 and a 200 day moving average of $5.10. Alpha Tau Medical has a 52 week low of $2.30 and a 52 week high of $8.60.

Alpha Tau Medical (NASDAQ:DRTS) last announced its quarterly earnings results on Wednesday, March 11th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). On average, research analysts anticipate that Alpha Tau Medical will post -0.45 earnings per share for the current year.

Institutional Investors Weigh In On Alpha Tau Medical

A number of institutional investors have recently made changes to their positions in the company. Apella Capital LLC purchased a new position in shares of Alpha Tau Medical in the fourth quarter worth $1,892,000. Daytona Street Capital LLC purchased a new position in Alpha Tau Medical in the 4th quarter worth about $749,000. Mariner LLC raised its position in Alpha Tau Medical by 185.8% in the 3rd quarter. Mariner LLC now owns 123,250 shares of the company’s stock worth $556,000 after buying an additional 80,129 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Alpha Tau Medical by 185.7% during the fourth quarter. Millennium Management LLC now owns 107,815 shares of the company’s stock valued at $534,000 after purchasing an additional 70,081 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in Alpha Tau Medical by 2,779.1% during the third quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after purchasing an additional 21,677 shares during the period. Hedge funds and other institutional investors own 2.65% of the company’s stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.